A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
収録刊行物
-
- Annals of Oncology
-
Annals of Oncology 31 (5), 619-625, 2020-05
Elsevier BV